nodes	percent_of_prediction	percent_of_DWPC	metapath
Brimonidine—Respiratory failure—Vandetanib—thyroid cancer	0.0169	0.0169	CcSEcCtD
Brimonidine—Dry eye—Vandetanib—thyroid cancer	0.0153	0.0153	CcSEcCtD
Brimonidine—Lethargy—Vandetanib—thyroid cancer	0.0123	0.0123	CcSEcCtD
Brimonidine—Rash papular—Epirubicin—thyroid cancer	0.0111	0.0111	CcSEcCtD
Brimonidine—Dry skin—Vandetanib—thyroid cancer	0.011	0.011	CcSEcCtD
Brimonidine—Nasopharyngitis—Vandetanib—thyroid cancer	0.0108	0.0108	CcSEcCtD
Brimonidine—Influenza—Vandetanib—thyroid cancer	0.0104	0.0104	CcSEcCtD
Brimonidine—Rash papular—Doxorubicin—thyroid cancer	0.0103	0.0103	CcSEcCtD
Brimonidine—Bronchitis—Vandetanib—thyroid cancer	0.01	0.01	CcSEcCtD
Brimonidine—Depression—Vandetanib—thyroid cancer	0.00924	0.00924	CcSEcCtD
Brimonidine—Conjunctivitis—Vandetanib—thyroid cancer	0.00901	0.00901	CcSEcCtD
Brimonidine—Sinusitis—Vandetanib—thyroid cancer	0.0087	0.0087	CcSEcCtD
Brimonidine—Bradycardia—Vandetanib—thyroid cancer	0.00847	0.00847	CcSEcCtD
Brimonidine—Muscle relaxant therapy—Epirubicin—thyroid cancer	0.0083	0.0083	CcSEcCtD
Brimonidine—Visual impairment—Vandetanib—thyroid cancer	0.00802	0.00802	CcSEcCtD
Brimonidine—Hypotonia—Epirubicin—thyroid cancer	0.00786	0.00786	CcSEcCtD
Brimonidine—Eye disorder—Vandetanib—thyroid cancer	0.00778	0.00778	CcSEcCtD
Brimonidine—Cardiac disorder—Vandetanib—thyroid cancer	0.00772	0.00772	CcSEcCtD
Brimonidine—Muscle relaxant therapy—Doxorubicin—thyroid cancer	0.00768	0.00768	CcSEcCtD
Brimonidine—Angiopathy—Vandetanib—thyroid cancer	0.00755	0.00755	CcSEcCtD
Brimonidine—Mediastinal disorder—Vandetanib—thyroid cancer	0.0075	0.0075	CcSEcCtD
Brimonidine—Blindness—Epirubicin—thyroid cancer	0.00746	0.00746	CcSEcCtD
Brimonidine—Dry skin—Sorafenib—thyroid cancer	0.00744	0.00744	CcSEcCtD
Brimonidine—Arrhythmia—Vandetanib—thyroid cancer	0.00743	0.00743	CcSEcCtD
Brimonidine—Body temperature decreased—Epirubicin—thyroid cancer	0.00737	0.00737	CcSEcCtD
Brimonidine—Hypothermia—Epirubicin—thyroid cancer	0.00737	0.00737	CcSEcCtD
Brimonidine—Mental disorder—Vandetanib—thyroid cancer	0.00729	0.00729	CcSEcCtD
Brimonidine—Hypotonia—Doxorubicin—thyroid cancer	0.00727	0.00727	CcSEcCtD
Brimonidine—Nasopharyngitis—Sorafenib—thyroid cancer	0.00726	0.00726	CcSEcCtD
Brimonidine—Dysgeusia—Vandetanib—thyroid cancer	0.00709	0.00709	CcSEcCtD
Brimonidine—Lacrimation—Epirubicin—thyroid cancer	0.00703	0.00703	CcSEcCtD
Brimonidine—Blindness—Doxorubicin—thyroid cancer	0.0069	0.0069	CcSEcCtD
Brimonidine—Vision blurred—Vandetanib—thyroid cancer	0.00683	0.00683	CcSEcCtD
Brimonidine—Body temperature decreased—Doxorubicin—thyroid cancer	0.00682	0.00682	CcSEcCtD
Brimonidine—Hypothermia—Doxorubicin—thyroid cancer	0.00682	0.00682	CcSEcCtD
Brimonidine—Lacrimation—Doxorubicin—thyroid cancer	0.0065	0.0065	CcSEcCtD
Brimonidine—Keratitis—Epirubicin—thyroid cancer	0.00637	0.00637	CcSEcCtD
Brimonidine—Loss of consciousness—Vandetanib—thyroid cancer	0.00637	0.00637	CcSEcCtD
Brimonidine—Cough—Vandetanib—thyroid cancer	0.00632	0.00632	CcSEcCtD
Brimonidine—Hypertension—Vandetanib—thyroid cancer	0.00625	0.00625	CcSEcCtD
Brimonidine—Arthralgia—Vandetanib—thyroid cancer	0.00617	0.00617	CcSEcCtD
Brimonidine—Chest pain—Vandetanib—thyroid cancer	0.00617	0.00617	CcSEcCtD
Brimonidine—Anxiety—Vandetanib—thyroid cancer	0.00615	0.00615	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00612	0.00612	CcSEcCtD
Brimonidine—Dry mouth—Vandetanib—thyroid cancer	0.00603	0.00603	CcSEcCtD
Brimonidine—Burning sensation—Epirubicin—thyroid cancer	0.00595	0.00595	CcSEcCtD
Brimonidine—Oedema—Vandetanib—thyroid cancer	0.00591	0.00591	CcSEcCtD
Brimonidine—Keratitis—Doxorubicin—thyroid cancer	0.00589	0.00589	CcSEcCtD
Brimonidine—Infection—Vandetanib—thyroid cancer	0.00587	0.00587	CcSEcCtD
Brimonidine—Nervous system disorder—Vandetanib—thyroid cancer	0.0058	0.0058	CcSEcCtD
Brimonidine—Skin disorder—Vandetanib—thyroid cancer	0.00574	0.00574	CcSEcCtD
Brimonidine—Burning sensation—Doxorubicin—thyroid cancer	0.0055	0.0055	CcSEcCtD
Brimonidine—Scotoma—Epirubicin—thyroid cancer	0.00544	0.00544	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00539	0.00539	CcSEcCtD
Brimonidine—Insomnia—Vandetanib—thyroid cancer	0.00535	0.00535	CcSEcCtD
Brimonidine—Paraesthesia—Vandetanib—thyroid cancer	0.00531	0.00531	CcSEcCtD
Brimonidine—Dyspnoea—Vandetanib—thyroid cancer	0.00527	0.00527	CcSEcCtD
Brimonidine—Feeling hot—Epirubicin—thyroid cancer	0.00526	0.00526	CcSEcCtD
Brimonidine—Cardiac disorder—Sorafenib—thyroid cancer	0.00521	0.00521	CcSEcCtD
Brimonidine—Flushing—Sorafenib—thyroid cancer	0.00521	0.00521	CcSEcCtD
Brimonidine—Dyspepsia—Vandetanib—thyroid cancer	0.0052	0.0052	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.0051	0.0051	CcSEcCtD
Brimonidine—Stinging—Epirubicin—thyroid cancer	0.0051	0.0051	CcSEcCtD
Brimonidine—Fatigue—Vandetanib—thyroid cancer	0.0051	0.0051	CcSEcCtD
Brimonidine—Angiopathy—Sorafenib—thyroid cancer	0.00509	0.00509	CcSEcCtD
Brimonidine—Immune system disorder—Sorafenib—thyroid cancer	0.00507	0.00507	CcSEcCtD
Brimonidine—Mediastinal disorder—Sorafenib—thyroid cancer	0.00506	0.00506	CcSEcCtD
Brimonidine—Pain—Vandetanib—thyroid cancer	0.00506	0.00506	CcSEcCtD
Brimonidine—Scotoma—Doxorubicin—thyroid cancer	0.00503	0.00503	CcSEcCtD
Brimonidine—Arrhythmia—Sorafenib—thyroid cancer	0.00501	0.00501	CcSEcCtD
Brimonidine—Mental disorder—Sorafenib—thyroid cancer	0.00492	0.00492	CcSEcCtD
Brimonidine—Erythema—Sorafenib—thyroid cancer	0.00489	0.00489	CcSEcCtD
Brimonidine—Feeling hot—Doxorubicin—thyroid cancer	0.00487	0.00487	CcSEcCtD
Brimonidine—Dysgeusia—Sorafenib—thyroid cancer	0.00478	0.00478	CcSEcCtD
Brimonidine—Stinging—Doxorubicin—thyroid cancer	0.00472	0.00472	CcSEcCtD
Brimonidine—Vasodilation procedure—Epirubicin—thyroid cancer	0.0047	0.0047	CcSEcCtD
Brimonidine—Vasodilation—Epirubicin—thyroid cancer	0.0047	0.0047	CcSEcCtD
Brimonidine—Arthropathy—Epirubicin—thyroid cancer	0.00454	0.00454	CcSEcCtD
Brimonidine—Lacrimation increased—Epirubicin—thyroid cancer	0.00448	0.00448	CcSEcCtD
Brimonidine—Syncope—Sorafenib—thyroid cancer	0.00438	0.00438	CcSEcCtD
Brimonidine—Vasodilation—Doxorubicin—thyroid cancer	0.00435	0.00435	CcSEcCtD
Brimonidine—Vasodilation procedure—Doxorubicin—thyroid cancer	0.00435	0.00435	CcSEcCtD
Brimonidine—Loss of consciousness—Sorafenib—thyroid cancer	0.00429	0.00429	CcSEcCtD
Brimonidine—Cough—Sorafenib—thyroid cancer	0.00426	0.00426	CcSEcCtD
Brimonidine—Asthenia—Vandetanib—thyroid cancer	0.00424	0.00424	CcSEcCtD
Brimonidine—Hypertension—Sorafenib—thyroid cancer	0.00422	0.00422	CcSEcCtD
Brimonidine—Arthropathy—Doxorubicin—thyroid cancer	0.0042	0.0042	CcSEcCtD
Brimonidine—Pruritus—Vandetanib—thyroid cancer	0.00418	0.00418	CcSEcCtD
Brimonidine—Arthralgia—Sorafenib—thyroid cancer	0.00416	0.00416	CcSEcCtD
Brimonidine—Myalgia—Sorafenib—thyroid cancer	0.00416	0.00416	CcSEcCtD
Brimonidine—Lacrimation increased—Doxorubicin—thyroid cancer	0.00415	0.00415	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00413	0.00413	CcSEcCtD
Brimonidine—Dermatitis contact—Epirubicin—thyroid cancer	0.00408	0.00408	CcSEcCtD
Brimonidine—Dry mouth—Sorafenib—thyroid cancer	0.00407	0.00407	CcSEcCtD
Brimonidine—Infection—Sorafenib—thyroid cancer	0.00396	0.00396	CcSEcCtD
Brimonidine—Shock—Sorafenib—thyroid cancer	0.00392	0.00392	CcSEcCtD
Brimonidine—Nervous system disorder—Sorafenib—thyroid cancer	0.00391	0.00391	CcSEcCtD
Brimonidine—Dizziness—Vandetanib—thyroid cancer	0.00391	0.00391	CcSEcCtD
Brimonidine—Skin disorder—Sorafenib—thyroid cancer	0.00387	0.00387	CcSEcCtD
Brimonidine—Dry eye—Epirubicin—thyroid cancer	0.00382	0.00382	CcSEcCtD
Brimonidine—Dermatitis contact—Doxorubicin—thyroid cancer	0.00378	0.00378	CcSEcCtD
Brimonidine—Coma—Epirubicin—thyroid cancer	0.00377	0.00377	CcSEcCtD
Brimonidine—Rash—Vandetanib—thyroid cancer	0.00373	0.00373	CcSEcCtD
Brimonidine—Dermatitis—Vandetanib—thyroid cancer	0.00372	0.00372	CcSEcCtD
Brimonidine—Headache—Vandetanib—thyroid cancer	0.0037	0.0037	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00363	0.00363	CcSEcCtD
Brimonidine—Abnormal vision—Epirubicin—thyroid cancer	0.0036	0.0036	CcSEcCtD
Brimonidine—Dyspnoea—Sorafenib—thyroid cancer	0.00356	0.00356	CcSEcCtD
Brimonidine—Dry eye—Doxorubicin—thyroid cancer	0.00353	0.00353	CcSEcCtD
Brimonidine—Nausea—Vandetanib—thyroid cancer	0.00351	0.00351	CcSEcCtD
Brimonidine—Dyspepsia—Sorafenib—thyroid cancer	0.00351	0.00351	CcSEcCtD
Brimonidine—Coma—Doxorubicin—thyroid cancer	0.00349	0.00349	CcSEcCtD
Brimonidine—Diabetes mellitus—Epirubicin—thyroid cancer	0.00345	0.00345	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00344	0.00344	CcSEcCtD
Brimonidine—Fatigue—Sorafenib—thyroid cancer	0.00344	0.00344	CcSEcCtD
Brimonidine—Pain—Sorafenib—thyroid cancer	0.00341	0.00341	CcSEcCtD
Brimonidine—Abnormal vision—Doxorubicin—thyroid cancer	0.00333	0.00333	CcSEcCtD
Brimonidine—Eye pain—Epirubicin—thyroid cancer	0.00332	0.00332	CcSEcCtD
Brimonidine—Diabetes mellitus—Doxorubicin—thyroid cancer	0.00319	0.00319	CcSEcCtD
Brimonidine—Eye pain—Doxorubicin—thyroid cancer	0.00307	0.00307	CcSEcCtD
Brimonidine—Lethargy—Epirubicin—thyroid cancer	0.00306	0.00306	CcSEcCtD
Brimonidine—Osteoarthritis—Epirubicin—thyroid cancer	0.003	0.003	CcSEcCtD
Brimonidine—Hypersensitivity—Sorafenib—thyroid cancer	0.00294	0.00294	CcSEcCtD
Brimonidine—Face oedema—Epirubicin—thyroid cancer	0.00289	0.00289	CcSEcCtD
Brimonidine—Asthenia—Sorafenib—thyroid cancer	0.00286	0.00286	CcSEcCtD
Brimonidine—Lethargy—Doxorubicin—thyroid cancer	0.00283	0.00283	CcSEcCtD
Brimonidine—Pruritus—Sorafenib—thyroid cancer	0.00282	0.00282	CcSEcCtD
Brimonidine—Osteoarthritis—Doxorubicin—thyroid cancer	0.00277	0.00277	CcSEcCtD
Brimonidine—Dry skin—Epirubicin—thyroid cancer	0.00275	0.00275	CcSEcCtD
Brimonidine—Nasopharyngitis—Epirubicin—thyroid cancer	0.00268	0.00268	CcSEcCtD
Brimonidine—Face oedema—Doxorubicin—thyroid cancer	0.00268	0.00268	CcSEcCtD
Brimonidine—Dizziness—Sorafenib—thyroid cancer	0.00264	0.00264	CcSEcCtD
Brimonidine—Influenza—Epirubicin—thyroid cancer	0.00259	0.00259	CcSEcCtD
Brimonidine—Dry skin—Doxorubicin—thyroid cancer	0.00254	0.00254	CcSEcCtD
Brimonidine—Rash—Sorafenib—thyroid cancer	0.00251	0.00251	CcSEcCtD
Brimonidine—Dermatitis—Sorafenib—thyroid cancer	0.00251	0.00251	CcSEcCtD
Brimonidine—Headache—Sorafenib—thyroid cancer	0.0025	0.0025	CcSEcCtD
Brimonidine—Bronchitis—Epirubicin—thyroid cancer	0.00249	0.00249	CcSEcCtD
Brimonidine—Nasopharyngitis—Doxorubicin—thyroid cancer	0.00248	0.00248	CcSEcCtD
Brimonidine—Influenza—Doxorubicin—thyroid cancer	0.0024	0.0024	CcSEcCtD
Brimonidine—Nausea—Sorafenib—thyroid cancer	0.00237	0.00237	CcSEcCtD
Brimonidine—Drowsiness—Epirubicin—thyroid cancer	0.00231	0.00231	CcSEcCtD
Brimonidine—Bronchitis—Doxorubicin—thyroid cancer	0.00231	0.00231	CcSEcCtD
Brimonidine—Conjunctivitis—Epirubicin—thyroid cancer	0.00225	0.00225	CcSEcCtD
Brimonidine—Sinusitis—Epirubicin—thyroid cancer	0.00217	0.00217	CcSEcCtD
Brimonidine—Drowsiness—Doxorubicin—thyroid cancer	0.00214	0.00214	CcSEcCtD
Brimonidine—Bradycardia—Epirubicin—thyroid cancer	0.00211	0.00211	CcSEcCtD
Brimonidine—Rhinitis—Epirubicin—thyroid cancer	0.00208	0.00208	CcSEcCtD
Brimonidine—Conjunctivitis—Doxorubicin—thyroid cancer	0.00208	0.00208	CcSEcCtD
Brimonidine—Pharyngitis—Epirubicin—thyroid cancer	0.00206	0.00206	CcSEcCtD
Brimonidine—Sinusitis—Doxorubicin—thyroid cancer	0.00201	0.00201	CcSEcCtD
Brimonidine—Visual impairment—Epirubicin—thyroid cancer	0.002	0.002	CcSEcCtD
Brimonidine—Bradycardia—Doxorubicin—thyroid cancer	0.00195	0.00195	CcSEcCtD
Brimonidine—Eye disorder—Epirubicin—thyroid cancer	0.00194	0.00194	CcSEcCtD
Brimonidine—Cardiac disorder—Epirubicin—thyroid cancer	0.00193	0.00193	CcSEcCtD
Brimonidine—Flushing—Epirubicin—thyroid cancer	0.00193	0.00193	CcSEcCtD
Brimonidine—Rhinitis—Doxorubicin—thyroid cancer	0.00192	0.00192	CcSEcCtD
Brimonidine—Pharyngitis—Doxorubicin—thyroid cancer	0.0019	0.0019	CcSEcCtD
Brimonidine—Angiopathy—Epirubicin—thyroid cancer	0.00188	0.00188	CcSEcCtD
Brimonidine—Immune system disorder—Epirubicin—thyroid cancer	0.00187	0.00187	CcSEcCtD
Brimonidine—Mediastinal disorder—Epirubicin—thyroid cancer	0.00187	0.00187	CcSEcCtD
Brimonidine—Arrhythmia—Epirubicin—thyroid cancer	0.00185	0.00185	CcSEcCtD
Brimonidine—Visual impairment—Doxorubicin—thyroid cancer	0.00185	0.00185	CcSEcCtD
Brimonidine—Mental disorder—Epirubicin—thyroid cancer	0.00182	0.00182	CcSEcCtD
Brimonidine—Erythema—Epirubicin—thyroid cancer	0.00181	0.00181	CcSEcCtD
Brimonidine—Eye disorder—Doxorubicin—thyroid cancer	0.00179	0.00179	CcSEcCtD
Brimonidine—Flushing—Doxorubicin—thyroid cancer	0.00178	0.00178	CcSEcCtD
Brimonidine—Cardiac disorder—Doxorubicin—thyroid cancer	0.00178	0.00178	CcSEcCtD
Brimonidine—Dysgeusia—Epirubicin—thyroid cancer	0.00177	0.00177	CcSEcCtD
Brimonidine—Angiopathy—Doxorubicin—thyroid cancer	0.00174	0.00174	CcSEcCtD
Brimonidine—Immune system disorder—Doxorubicin—thyroid cancer	0.00173	0.00173	CcSEcCtD
Brimonidine—Mediastinal disorder—Doxorubicin—thyroid cancer	0.00173	0.00173	CcSEcCtD
Brimonidine—Arrhythmia—Doxorubicin—thyroid cancer	0.00171	0.00171	CcSEcCtD
Brimonidine—Vision blurred—Epirubicin—thyroid cancer	0.0017	0.0017	CcSEcCtD
Brimonidine—Mental disorder—Doxorubicin—thyroid cancer	0.00168	0.00168	CcSEcCtD
Brimonidine—Erythema—Doxorubicin—thyroid cancer	0.00167	0.00167	CcSEcCtD
Brimonidine—Dysgeusia—Doxorubicin—thyroid cancer	0.00164	0.00164	CcSEcCtD
Brimonidine—Syncope—Epirubicin—thyroid cancer	0.00162	0.00162	CcSEcCtD
Brimonidine—Palpitations—Epirubicin—thyroid cancer	0.0016	0.0016	CcSEcCtD
Brimonidine—Loss of consciousness—Epirubicin—thyroid cancer	0.00159	0.00159	CcSEcCtD
Brimonidine—Cough—Epirubicin—thyroid cancer	0.00158	0.00158	CcSEcCtD
Brimonidine—Vision blurred—Doxorubicin—thyroid cancer	0.00157	0.00157	CcSEcCtD
Brimonidine—Hypertension—Epirubicin—thyroid cancer	0.00156	0.00156	CcSEcCtD
Brimonidine—Arthralgia—Epirubicin—thyroid cancer	0.00154	0.00154	CcSEcCtD
Brimonidine—Myalgia—Epirubicin—thyroid cancer	0.00154	0.00154	CcSEcCtD
Brimonidine—Chest pain—Epirubicin—thyroid cancer	0.00154	0.00154	CcSEcCtD
Brimonidine—Anxiety—Epirubicin—thyroid cancer	0.00153	0.00153	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00153	0.00153	CcSEcCtD
Brimonidine—Discomfort—Epirubicin—thyroid cancer	0.00152	0.00152	CcSEcCtD
Brimonidine—Dry mouth—Epirubicin—thyroid cancer	0.0015	0.0015	CcSEcCtD
Brimonidine—Syncope—Doxorubicin—thyroid cancer	0.0015	0.0015	CcSEcCtD
Brimonidine—Palpitations—Doxorubicin—thyroid cancer	0.00148	0.00148	CcSEcCtD
Brimonidine—Oedema—Epirubicin—thyroid cancer	0.00147	0.00147	CcSEcCtD
Brimonidine—Loss of consciousness—Doxorubicin—thyroid cancer	0.00147	0.00147	CcSEcCtD
Brimonidine—Infection—Epirubicin—thyroid cancer	0.00146	0.00146	CcSEcCtD
Brimonidine—Cough—Doxorubicin—thyroid cancer	0.00146	0.00146	CcSEcCtD
Brimonidine—Shock—Epirubicin—thyroid cancer	0.00145	0.00145	CcSEcCtD
Brimonidine—Nervous system disorder—Epirubicin—thyroid cancer	0.00145	0.00145	CcSEcCtD
Brimonidine—Hypertension—Doxorubicin—thyroid cancer	0.00144	0.00144	CcSEcCtD
Brimonidine—Tachycardia—Epirubicin—thyroid cancer	0.00144	0.00144	CcSEcCtD
Brimonidine—Skin disorder—Epirubicin—thyroid cancer	0.00143	0.00143	CcSEcCtD
Brimonidine—Arthralgia—Doxorubicin—thyroid cancer	0.00142	0.00142	CcSEcCtD
Brimonidine—Chest pain—Doxorubicin—thyroid cancer	0.00142	0.00142	CcSEcCtD
Brimonidine—Myalgia—Doxorubicin—thyroid cancer	0.00142	0.00142	CcSEcCtD
Brimonidine—Anxiety—Doxorubicin—thyroid cancer	0.00142	0.00142	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.00141	0.00141	CcSEcCtD
Brimonidine—Discomfort—Doxorubicin—thyroid cancer	0.00141	0.00141	CcSEcCtD
Brimonidine—Dry mouth—Doxorubicin—thyroid cancer	0.00139	0.00139	CcSEcCtD
Brimonidine—Hypotension—Epirubicin—thyroid cancer	0.00138	0.00138	CcSEcCtD
Brimonidine—Oedema—Doxorubicin—thyroid cancer	0.00136	0.00136	CcSEcCtD
Brimonidine—Infection—Doxorubicin—thyroid cancer	0.00135	0.00135	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00134	0.00134	CcSEcCtD
Brimonidine—Shock—Doxorubicin—thyroid cancer	0.00134	0.00134	CcSEcCtD
Brimonidine—Nervous system disorder—Doxorubicin—thyroid cancer	0.00134	0.00134	CcSEcCtD
Brimonidine—Insomnia—Epirubicin—thyroid cancer	0.00133	0.00133	CcSEcCtD
Brimonidine—Tachycardia—Doxorubicin—thyroid cancer	0.00133	0.00133	CcSEcCtD
Brimonidine—Skin disorder—Doxorubicin—thyroid cancer	0.00132	0.00132	CcSEcCtD
Brimonidine—Paraesthesia—Epirubicin—thyroid cancer	0.00132	0.00132	CcSEcCtD
Brimonidine—Dyspnoea—Epirubicin—thyroid cancer	0.00131	0.00131	CcSEcCtD
Brimonidine—Somnolence—Epirubicin—thyroid cancer	0.00131	0.00131	CcSEcCtD
Brimonidine—Dyspepsia—Epirubicin—thyroid cancer	0.0013	0.0013	CcSEcCtD
Brimonidine—Hypotension—Doxorubicin—thyroid cancer	0.00127	0.00127	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00127	0.00127	CcSEcCtD
Brimonidine—Fatigue—Epirubicin—thyroid cancer	0.00127	0.00127	CcSEcCtD
Brimonidine—Pain—Epirubicin—thyroid cancer	0.00126	0.00126	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.00124	0.00124	CcSEcCtD
Brimonidine—Insomnia—Doxorubicin—thyroid cancer	0.00123	0.00123	CcSEcCtD
Brimonidine—Paraesthesia—Doxorubicin—thyroid cancer	0.00122	0.00122	CcSEcCtD
Brimonidine—Dyspnoea—Doxorubicin—thyroid cancer	0.00122	0.00122	CcSEcCtD
Brimonidine—Somnolence—Doxorubicin—thyroid cancer	0.00121	0.00121	CcSEcCtD
Brimonidine—Dyspepsia—Doxorubicin—thyroid cancer	0.0012	0.0012	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.00118	0.00118	CcSEcCtD
Brimonidine—Fatigue—Doxorubicin—thyroid cancer	0.00118	0.00118	CcSEcCtD
Brimonidine—Pain—Doxorubicin—thyroid cancer	0.00117	0.00117	CcSEcCtD
Brimonidine—Hypersensitivity—Epirubicin—thyroid cancer	0.00109	0.00109	CcSEcCtD
Brimonidine—Asthenia—Epirubicin—thyroid cancer	0.00106	0.00106	CcSEcCtD
Brimonidine—Pruritus—Epirubicin—thyroid cancer	0.00104	0.00104	CcSEcCtD
Brimonidine—Hypersensitivity—Doxorubicin—thyroid cancer	0.001	0.001	CcSEcCtD
Brimonidine—Asthenia—Doxorubicin—thyroid cancer	0.000978	0.000978	CcSEcCtD
Brimonidine—Dizziness—Epirubicin—thyroid cancer	0.000975	0.000975	CcSEcCtD
Brimonidine—Pruritus—Doxorubicin—thyroid cancer	0.000965	0.000965	CcSEcCtD
Brimonidine—Rash—Epirubicin—thyroid cancer	0.000929	0.000929	CcSEcCtD
Brimonidine—Dermatitis—Epirubicin—thyroid cancer	0.000928	0.000928	CcSEcCtD
Brimonidine—Headache—Epirubicin—thyroid cancer	0.000923	0.000923	CcSEcCtD
Brimonidine—Dizziness—Doxorubicin—thyroid cancer	0.000902	0.000902	CcSEcCtD
Brimonidine—Nausea—Epirubicin—thyroid cancer	0.000875	0.000875	CcSEcCtD
Brimonidine—Rash—Doxorubicin—thyroid cancer	0.00086	0.00086	CcSEcCtD
Brimonidine—Dermatitis—Doxorubicin—thyroid cancer	0.000859	0.000859	CcSEcCtD
Brimonidine—Headache—Doxorubicin—thyroid cancer	0.000854	0.000854	CcSEcCtD
Brimonidine—Nausea—Doxorubicin—thyroid cancer	0.00081	0.00081	CcSEcCtD
